

REC Number	IRAS No	Name of Trial	Min number of patients agreed to be recruited	Max number of patients agreed to be recruited	Date Trial Closed To Recruitment	Number of patients recruited at target date	Recruitment target date	Target Met?	Reason For Closure Of Trial
12/SC/0139	98125	A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAS			24/05/2016	0	24/05/2016		Recruitment Finished
13/SC/0092	113121	Phase III Placebo controlled study using siponimod (BAF132) in secondary progressive multiple sclerosis (CCRN 1056)	6	6	01/04/2016	6	01/04/2016	Y	Recruitment Finished
12/LO/0893	87695	NCRN422 ALCANZA - brentuximab vedotin vs investigator's choice in CD30+ cutaneous T-cell lymphoma	5	5	24/05/2016	0	24/05/2016	N	Recruitment Finished
12/LO/0491	98262	CCRN 829 (SURTAVI)	5	5	19/05/2016	1	19/05/2016	N	Recruitment Finished
REC1	110569	NCRN460	5	5	15/02/2016	10	15/02/2016	Y	Recruitment Finished
12/LO/1950	117042	ECHELON-1 (Millenium C25003)	8	8	01/04/2016	8	01/04/2016	Y	Recruitment Finished
13/NW/0006	114825	A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas	2	2	08/11/2016	0	08/11/2016	N	Recruitment Finished
13/NW/0692	134662	A multicenter, international, randomized, parallel group, double blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcomE with LINagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELIN	10	10	20/07/2016	11	20/07/2016	Y	Recruitment Finished
13/NI/0148	102251	OCS Sparing Study	14	14	24/05/2016	18	24/05/2016	Y	Recruitment Finished
13/EE/0241	133773	CCRN 2278 - SIGNATURE	2	2	01/04/2016	3	01/04/2016	Y	Recruitment Finished
13/EM/0251	131150	RELAX 2 - Serelaxin when added to standard therapy in acute heart failure	6	6	03/08/2016	13	03/08/2016	Y	Recruitment Finished
13/SC/0490	135889	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH SEVERE UNCONTROLLED ASTHMA WHO ARE ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICAT	3	3	30/06/2016	2	30/06/2016	N	Recruitment Finished
14/NE/0105	158216	A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	2	2	24/02/2016	3	24/02/2016	Y	Recruitment Finished
13/EM/0284	133087	NCRN552 - oral LDK378 versus standard chemotherapy in ALK- rearranged (ALK-positive) NSCLC	1	1	01/04/2016	2	01/04/2016	Y	Recruitment Finished
14/SC/1311	155403	MCRN3165 (SD744) Cubist PSI Osteomyelitis	1	1	04/07/2016	0	04/07/2016	N	Recruitment Finished
14/SC/0181	148882	Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis- Associated Pain			01/02/2016	1	01/02/2016		Recruitment Finished
13/LO/1517	131080	Phase 3, Randomized, Open Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis	2	2	01/07/2016	15	01/07/2016	Y	Recruitment Finished
14/LO/0673	146391	Phase 3, Randomised, Placebo-Controlled Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in patients with Multiple Myeloma Following Autologous Stem Cell Transplant	8	8	16/03/2016	3	16/03/2016	N	Recruitment Finished
14/LO/0717	149876	NCRN - 3023 - Bosutinib vs Imatinib in Chronic Phase Philadelphia Chromosome Positive CML	3	3	01/04/2016	4	01/04/2016	Y	Recruitment Finished

REC Number	IRAS No	Name of Trial	Min number of patients agreed to be recruited	Max number of patients agreed to be recruited	Date Trial Closed To Recruitment	Number of patients recruited at target date	Recruitment target date	Target Met?	Reason For Closure Of Trial
14/NE/1018	150960	A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD)	6	6	03/11/2016	18	03/11/2016	Y	Recruitment Finished
14/WM/0170	154982	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post- polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis	2	2	15/01/2016	1	15/01/2016	N	Recruitment Finished
14/EM/0186	150545	PERSIST 2 - A Randomised Controlled Phase III Study Of Oral Pacritinib Versus Best Available Therapy In Patients With Thrombocytopenia And Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Or Post-Essential Thrombocythemia Myelofibrosis	2	2	01/04/2016	2	01/04/2016	Y	Recruitment Finished
14/LO/2011	159926	DUAL antithrombotic therapy with dabigatran etexilate (RE-DUAL PCI)	10	10	31/10/2016	2	31/10/2016	N	Recruitment Finished
14/EM/1003	155235	RENA3444 (BRIGHT-SC)	4	4	26/04/2016	4	26/04/2016	Y	Recruitment Finished
14/NE/1072	153275	A Phase II, Randomised, Double Blind, Placebo-controlled Bronscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled corticosteroids and a second controller medication	4	4	04/08/2016	6	04/08/2016	Y	Recruitment Finished
14/LO/1406	156883	A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT-199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED AND REFRACTORY FOLLICULAR NON HODGKIN'S L	2	2	21/03/2016	2	21/03/2016	Y	Recruitment Finished
14/LO/1193	151954	3345 CARD STRENGTH	5	5	03/08/2016	0	03/08/2016	N	Recruitment Finished
14/WS/0103	149375	CANC - 3548			01/04/2016	1	01/04/2016		Recruitment Finished
14/LO/1798	161154	A Phase III open-label multicenter randomised study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 antibody) compared to chemotherapy in patients with locally advanced or metastatic bladder cancer after the failure with platinum-cont	2	2	17/05/2016	4	17/05/2016	Y	Recruitment Finished
14/LO/1426	158013	NCRN - 2960 - Unresected Stage IIIB - IVM1a Melanoma Treated with Talimogene Laherparepvec	5	5	09/06/2016	1	09/06/2016	N	Recruitment Finished
14/NE/1214	162696	ABBVIE - M14-359	5	5	28/07/2016	8	28/07/2016	Y	Recruitment Finished
15/LO/0718	174025	CHIL3887 mepolizumab in children from 6 to 11 years of age with severe eosinophilic asthma	2	2	28/06/2016	0	28/06/2016	N	Recruitment Finished
14/WS/1146	166537	Multicenter, randomised, double-blind, double-dummy, active- comparator event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ES)	10	10	23/12/2016	6	23/12/2016	N	Recruitment Finished
14/LO/1443	149317	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis	2	2	01/01/2016	5	01/01/2016	Y	Recruitment Finished
14/SS/1048	154401	A Phase 3b, Multicenter, Randomized-withdrawal, Placebo- controlled, Double- blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Splitdose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Earl	5	5	31/03/2016	6	31/03/2016	Y	Recruitment Finished

REC Number	IRAS No	Name of Trial	Min number of patients agreed to be recruited	Max number of patients agreed to be recruited	Date Trial Closed To Recruitment	Number of patients recruited at target date	Recruitment target date	Target Met?	Reason For Closure Of Trial
15/LO/0288	169194	PLAIT - A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia	2	2	06/05/2016	0	06/05/2016	N	Recruitment Finished
14/NW/1405	164557	Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101	6	6	20/05/2016	7	20/05/2016	Y	Recruitment Finished
15/SC/0054	171682	CheckMate 238 - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence (CheckMate 238: CHECKpo	3	3	16/03/2016	3	16/03/2016	Y	Recruitment Finished
15/LO/0691	174324	Checkmate 171: An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen for t	8	8	06/07/2016	15	06/07/2016	Y	Recruitment Finished
15/WM/0009	165367	A Phase 3, Randomised, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High- dose Th	3	3	15/07/2016	0	15/07/2016	N	Recruitment Finished
15/EE/0161	177265	A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of Empagliflozin as Adjunctive to insulin over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE-2)	5	5	26/09/2016	6	26/09/2016	Y	Recruitment Finished
15/NW/0319	174853	A phase 3. randomized, double-blind, placebo-group, multicenter study to evaluate the efficacy, safety, and tolerability of LX4211 as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin the	7	7	01/04/2016	5	01/04/2016	N	Recruitment Finished
15/WM/0211	167913	An open-label Phase 1b study of ACP-196 in subjects with multiple myeloma	7	7	15/03/2016	3	15/03/2016	N	Recruitment Finished
12/LO/0803	99497	BEECH	3	3	01/04/2016	1	01/04/2016	N	Recruitment Finished
15/SC/0475	174852	An Open-Label, Randomized Phase 3 Trial of Nivolumab and Nivolumab plus Ipilimumab versus Platinum Doublet Chemotherapy in Patients with Chemotherapy-Na?ve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)			19/12/2016	14	19/12/2016		Recruitment Finished
12/SC/0139	98125	SafeHer: Safety study with subcutaneous Trastuzumab in breast cancer	10	10	23/09/2016	0	24/05/2016	N	Recruitment Finished
12/EM/0204	106365	Safety and tolerability of ONO-4059 in patients with NHL & CLL	7	7	17/06/2016	0	17/06/2016	N	Recruitment Finished
14/SW/1062	156164	ACP-196 in subjects with Relapsed or Refractory de Novo ABC DLBCL	17	17	26/01/2016	0	26/01/2016	N	Recruitment Finished
14/LO/1996	163827	VS-6063-104 Phase 1 study in relapsed malignant mesothelioma	14	14	01/04/2016	0	30/03/2016	N	Recruitment Finished
15/ES/0115	183031	Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation Positive Non Small Cell Lung Cancer (NSCLC) Who Have Received Prio			01/09/2016	0	01/09/2016		Recruitment Finished
15/LO/1807	187302	An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum based First Line Chemotherapy (Checkmate 331)			26/09/2016	0	26/09/2016		Recruitment Finished

REC Number	IRAS No	Name of Trial	Min number of patients agreed to be recruited	Max number of patients agreed to be recruited	Date Trial Closed To Recruitment	Number of patients recruited at target date	Recruitment target date	Target Met?	Reason For Closure Of Trial
15/WS/0135	183471	A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS- 4059 in Combination with other Targeted Anti-cancer Therapies in Subjects with B-cell Malignancies	6	6	24/11/2016	9	24/11/2016	Y	Recruitment Finished
14/NW/0218	149200	GLYCEMIC CONTROL AND TREATMENT SATISFACTION USING FINESSE VERSUS PEN FOR INITIATING BOLUS INSULIN DOSING IN TYPE 2 DIABETES MELLITUS PATIENTS NOT ACHIEVING GLYCEMIC TARGETS ON BASAL INSULIN WITH/WITHOUT ANTI- HYPERGLYCEMIC AGENTS	5	5	24/08/2016	3	24/08/2016	N	Recruitment Finished
13/EE/0345	135062	Multi-arm, non-randomised, open-label phase 1B study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel or as single agent in subjects with solid malignancies and deregulated FGF pathway signalling			02/08/2016	2	02/08/2016		Recruitment Finished
14/EM/1267	166568	LCZ696 in patients from Paradigm HF study	5	5	31/07/2016	5	31/07/2016	Y	Recruitment Finished
15/LO/0861	179571	RESP 4558	4	4	01/12/2016	4	01/12/2016	Y	Recruitment Finished
15/LO/1500	187068	Drug-drug interaction study with nintedanib and pirfenidone	4	4	31/12/2016	2	31/12/2016	N	Recruitment Finished
16/LO/0152	193306	DIAB 5013 A real-world, point of care, randomized, 2-arm, open, 52-week study to evaluate the effect of a digital disease management support tool in patients with type 2 diabetes mellitus.	25	25	14/10/2016	14	14/10/2016	N	Recruitment Finished
15/LO/0519	176955	A Multiarm-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS- 663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1	2	2	21/12/2016	0	21/12/2016	N	Recruitment Finished
15/NW/0626	184626	A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel- group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes	5	5	19/08/2016	1	19/08/2016	N	Recruitment Finished
15/NW/0668	173723	FUTURE 5: A phase III, randomised, double-blind, placebo controlled multicentre study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficiency (including inhibition of structural damage), safety and tolerability	10	10	23/09/2016	2	23/09/2016	N	Recruitment Finished
15/SC/0699	192903	Clinical Study Protocol M13-549 A Phase 3, Randomized, Double- Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti- Rheum	3	3	22/12/2016	1	22/12/2016	N	Recruitment Finished
15/WM/0263	184150	An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects with Relapsed/Refractory B-cell malignancies			01/04/2016	0	01/04/2016		Recruitment Finished
15/SC/0397	183591	NJ002			25/05/2016	0	25/05/2016		Recruitment Finished
15/LO/2066	193084	4222: Efficacy And Long-Term Safety Of Oral Semaglutide Versus Sitagliptin In Subjects With Type 2 Diabetes Mellitus. A 78-Week, Randomised, Double-Blind, Double-Dummy, Active-Controlled, Parallel-Group, Multi-Centre, Multi-National, Four-Armed Trial	4	4	10/07/2016	5	10/07/2016	Y	Recruitment Finished
15/EE/0350	187779	A Phase III, randomised, double blind, placebo-controlled,parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to insulin therapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EAS)	3	3	21/12/2016	0	21/12/2016	N	Recruitment Finished
15/EM/0247	179169	Effect of Tralokinumab on Airway Inflammation in Asthma	6	6	30/11/2016	8	30/11/2016	Y	Recruitment Finished

REC Number	IRAS No	Name of Trial	Min number of patients agreed to be recruited	Max number of patients agreed to be recruited	Date Trial Closed To Recruitment	Number of patients recruited at target date	Recruitment target date	Target Met?	Reason For Closure Of Trial
16/EM/0006	191553	A 24 week, Multicentre, Randomized, Open Label, 2 ARm Parallel- group study evaluating the Efficacy and Safety of Patient - versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus	10	10	01/12/2016	9	01/12/2016	N	Recruitment Finished
16/NE/0014	192732	AF219-012: A 12-Week Study to Assess the Efficacy and Safety of AF-219 in Subjects with Treatment Refractory Chronic Cough	6	6	28/07/2016	9	28/07/2016	Y	Recruitment Finished
13/LO/0219	120842	CCRN 2144 - A Phase 2, Randomized, Double-Blind, Placebo- Controlled, Event-Driven, Multi-Center study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) CCRN 2074	2	2	18/05/2016	0	31/12/2016	N	Recruitment Finished
14/EM/1059	152516	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	2	2	25/05/2016	2	25/05/2016	Y	Recruitment Finished
13/NW/0003	117310	SEVERE SEPSIS / COAGULOPATHY TRIAL ART-123	6	6	31/05/2016	0	31/05/2016	N	Recruitment Finished